These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 27590272

  • 21. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [Abstract] [Full Text] [Related]

  • 22. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
    Szczyrek M, Mlak R, Krawczyk P, Wojas-Krawczyk K, Powrózek T, Szudy-Szczyrek A, Zwolak A, Daniluk J, Milanowski J.
    Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
    [Abstract] [Full Text] [Related]

  • 23. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
    Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M.
    Clin Lung Cancer; 2017 Mar; 18(2):e129-e136. PubMed ID: 27825639
    [Abstract] [Full Text] [Related]

  • 24. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
    Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P.
    Pharmacogenomics; 2014 Mar; 15(12):1565-74. PubMed ID: 25340731
    [Abstract] [Full Text] [Related]

  • 25. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 26. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T.
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
    [Abstract] [Full Text] [Related]

  • 27. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, Oh SC, Seo JH, Kim JS.
    Chemotherapy; 2016 Aug; 61(1):41-50. PubMed ID: 26517706
    [Abstract] [Full Text] [Related]

  • 28. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
    Ryu JS, Kim HJ, Shin ES, Nam HS, Cho JH, Lee JE.
    Oncol Res; 2012 Aug; 20(1):25-30. PubMed ID: 23035362
    [Abstract] [Full Text] [Related]

  • 29. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R, Krawczyk P, Homa-Mlak I, Powrózek T, Ciesielka M, Kozioł P, Milanowski J, Małecka-Massalska T.
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [Abstract] [Full Text] [Related]

  • 30. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
    Campa D, Müller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A.
    Int J Cancer; 2012 Dec 15; 131(12):2920-8. PubMed ID: 22473764
    [Abstract] [Full Text] [Related]

  • 31. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
    Najjar F, Alammar M, Bachour M, Almalla N, Altahan M, Alali A, Al-Massarani G.
    J Cancer Res Clin Oncol; 2015 Jan 15; 141(1):119-25. PubMed ID: 25037116
    [Abstract] [Full Text] [Related]

  • 32. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.
    Peng J, Yang LX, Zhao XY, Gao ZQ, Yang J, Wu WT, Wang HJ, Wang JC, Qian J, Chen HY, Jin L, Bai CX, Han BH, Wang WM, Lu DR.
    Tumour Biol; 2013 Apr 15; 34(2):953-61. PubMed ID: 23412975
    [Abstract] [Full Text] [Related]

  • 33. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.
    Clin Transl Oncol; 2006 Oct 15; 8(10):742-9. PubMed ID: 17074673
    [Abstract] [Full Text] [Related]

  • 34. Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
    Takeuchi A, Oguri T, Fukuda S, Sone K, Kagawa Y, Uemura T, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Tajiri T, Ohkubo H, Takemura M, Ito Y, Niimi A.
    Anticancer Res; 2020 Aug 15; 40(8):4245-4251. PubMed ID: 32727751
    [Abstract] [Full Text] [Related]

  • 35. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 15; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 36. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
    Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G.
    Cancer Epidemiol; 2016 Apr 15; 41():50-6. PubMed ID: 26816351
    [Abstract] [Full Text] [Related]

  • 37. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.
    Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, Tang Q, Zhou HH, Liu ZQ.
    CNS Neurosci Ther; 2012 Aug 15; 18(8):647-51. PubMed ID: 22630058
    [Abstract] [Full Text] [Related]

  • 38. The association of transporter genes polymorphisms and lung cancer chemotherapy response.
    Wang Y, Yin JY, Li XP, Chen J, Qian CY, Zheng Y, Fu YL, Chen ZY, Zhou HH, Liu ZQ.
    PLoS One; 2014 Aug 15; 9(3):e91967. PubMed ID: 24643204
    [Abstract] [Full Text] [Related]

  • 39. Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
    Kumpiro S, Sriuranpong V, Areepium N.
    Asian Pac J Cancer Prev; 2016 Aug 15; 17(9):4391-4394. PubMed ID: 27797249
    [Abstract] [Full Text] [Related]

  • 40. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.
    Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB.
    Am J Physiol Renal Physiol; 2010 Apr 15; 298(4):F997-F1005. PubMed ID: 20053795
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.